Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Verona Pharma has agreed a new $400 million debt facility ... its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Citing preliminary unaudited results on Tuesday, Verona Pharma (NASDAQ ... for adults with chronic obstructive pulmonary disease (COPD) in June, and the company launched the product in August.

dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and ... visits and report a lack of control of their COPD symptoms, the firm added.

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary ...